Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma

Zhong,Hua; Xu,Lan; Zhong,Ji-Hua; Xiao,Fei; Liu,Qiang; Huang,Hong-Hui; Chen,Fang-Yuan

doi:10.3892/etm.2012.502

Clinical and prognostic significance of miR-155 and miR-146a expression levels in formalin-fixed/paraffin-embedded tissue of patients with diffuse large B-cell lymphoma

Authors:
- Hua Zhong
- Lan Xu
- Ji-Hua Zhong
- Fei Xiao
- Qiang Liu
- Hong-Hui Huang
- Fang-Yuan Chen
View Affiliations

Affiliations: Department of Hematology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200127, P.R. China, Department of Pathology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200127, P.R. China
Published online on: March 2, 2012 https://doi.org/10.3892/etm.2012.502
Pages: 763-770

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been found that aberrant expression of microRNAs (miRNAs) is strongly associated with carcinogenesis. In the present study, we investigated the expression of miR-155 and miR-146a in diffuse large B-cell lymphoma (DLBCL) patients (n=90). The expression levels of miR-155 and miR-146a were significantly higher in de novo DLBCL patients. miR-146a expression levels were associated with miR-155, lactate dehydrogenase, β 2 microglobulin, c-myc, International Prognostic Index status and Eastern Cooperative Oncology Group performance status. We found that patients with low miR-155 and miR-146a expression levels achieved a higher complete remission rate, higher overall response rate and longer progression-free survival time. Moreover, a high expression level of miR-155, but not miR-146a, was an independent indicator for chemotherapy protocol selection in our study. Patients with high expression of miR-155 received more survival benefits from rituximab treatment. These data suggest that miR-155 and miR-146a have potential as diagnostic and prognostic markers in DLBCL.

View Figures

View References

1.	Chen K and Rajewsky N: The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 8:93–103. 2007. View Article : Google Scholar : PubMed/NCBI
2.	Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 6:376–385. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Lawrie CH: MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy? Cell Mol Med. 12:1432–1444. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Calin GA, Ferracin M, Cimmino A, et al: A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Lawrie CH, Gal S, Dunlop HM, et al: Detection of elevated levels of tumour associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 141:672–675. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Kota SK and Balasubramanian S: Cancer therapy via modulation of microRNA levels: a promising future. Drug Discov Today. 15:733–740. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Coiffier B: Diffuse large cell lymphoma. Curr Opin Oncol. 13:325–334. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
11.	Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 194:1861–1874. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Thompson RC, Herscovitch M, Zhao I, et al: NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway. J Biol Chem. 286:1675–1682. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Braun T, Carvalho G, Fabre C, et al: Targeting NF-kappaB in hematologic malignancies. Cell Death Differ. 13:748–758. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Taganov KD, Boldin MP, Chang KJ, et al: NF-kappaB dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Li J, Smyth P, Flavin R, et al: Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 7:362007. View Article : Google Scholar : PubMed/NCBI
16.	Lawrie CH, Soneji S, Marafioti T, et al: MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 121:1156–1161. 2007. View Article : Google Scholar
17.	Nogai H, Dörken B and Lenz GJ: Pathogenesis of non-Hodgkin’s lymphoma. Clin Oncol. 29:1803–1811. 2011.
18.	Chen C, Ridzon DA, Broomer AJ, et al: Real-time quantificiation of microRNAs by stem-loop RT-PCR. Nucletic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
19.	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell. 122:6–7. 2005. View Article : Google Scholar : PubMed/NCBI
21.	Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res. 65:3509–3512. 2005. View Article : Google Scholar : PubMed/NCBI
22.	McManus MT: MicroRNAs and cancer. Semin Cancer Biol. 13:253–258. 2003. View Article : Google Scholar
23.	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Lawrie CH, Saunders NJ, Soneji S, et al: MicroRNA expression in lymphocyte development and malignancy. Leukemia. 22:1440–1446. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Lawrie CH, Chi JX, Taylor S, et al: Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med. 13:1248–1260. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Xi Y, Nakajima G, Gavin E, et al: Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 13:1668–1674. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Georgantas RW III, Hildreth R, Morisot S, et al: CD34⁺ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci USA. 104:2750–2755. 2007.PubMed/NCBI
28.	Eis PS, Tam W, Sun L, et al: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
29.	Kluiver J, Poppema S, de Jong D, et al: BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 207:243–249. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Chang TC, Yu D, Lee YS, et al: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 40:43–50. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Zhang H, Luo XQ, Zhang P, et al: MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 4:e78262009. View Article : Google Scholar : PubMed/NCBI
32.	Wang Y, Li Z, He C, et al: MicroRNA expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis. 44:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Visone R, Rassenti LZ, Veronese A, et al: Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood. 114:3872–3879. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Roldo C, Missiaglia E, Hagan JP, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol. 24:4677–4684. 2006. View Article : Google Scholar : PubMed/NCBI
35.	Volinia S, Galasso M, Costinean S, et al: Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 20:589–599. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Monticelli S, Ansel KM, Xiao C, et al: MicroRNA profiling of the murine hematopoietic system. Genome Biol. 6:R712005. View Article : Google Scholar : PubMed/NCBI
37.	Boominathan L: The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNA network. Cancer Metastasis Rev. 29:613–639. 2010. View Article : Google Scholar : PubMed/NCBI
38.	Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
39.	Thai TH, Calado DP, Casola S, et al: Regulation of the germinal center response by microRNA-155. Science. 316:604–608. 2007. View Article : Google Scholar : PubMed/NCBI
40.	Costinean S, Zanesi N, Pekarsky Y, et al: Pre-B cell proliferation and lymphoblastic leukemia/highgrade lymphoma in E (mu)-miR155 transgenic mice. Proc Natl Acad Sci USA. 103:7024–7029. 2006. View Article : Google Scholar : PubMed/NCBI
41.	Boldin MP, Taganov KD, Rao DS, et al: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 208:1189–1201. 2011. View Article : Google Scholar : PubMed/NCBI
42.	Lenz G, Wright GW, Emre NCT, et al: Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 105:13520–13525. 2008. View Article : Google Scholar : PubMed/NCBI